AU2022436042A1 - Method for detecting a phenotype and a function of a cd141+ dendritic cell subset and kit for use - Google Patents
Method for detecting a phenotype and a function of a cd141+ dendritic cell subset and kit for use Download PDFInfo
- Publication number
- AU2022436042A1 AU2022436042A1 AU2022436042A AU2022436042A AU2022436042A1 AU 2022436042 A1 AU2022436042 A1 AU 2022436042A1 AU 2022436042 A AU2022436042 A AU 2022436042A AU 2022436042 A AU2022436042 A AU 2022436042A AU 2022436042 A1 AU2022436042 A1 AU 2022436042A1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- dendritic cells
- detecting
- phenotype
- dendritic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 256
- 238000000034 method Methods 0.000 title claims description 13
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 50
- 239000011886 peripheral blood Substances 0.000 claims abstract description 50
- 102000006354 HLA-DR Antigens Human genes 0.000 claims abstract description 40
- 108010058597 HLA-DR Antigens Proteins 0.000 claims abstract description 40
- 238000004458 analytical method Methods 0.000 claims abstract description 33
- 238000001514 detection method Methods 0.000 claims abstract description 15
- 230000006870 function Effects 0.000 claims description 74
- 210000004027 cell Anatomy 0.000 claims description 48
- 238000011534 incubation Methods 0.000 claims description 44
- 239000007850 fluorescent dye Substances 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 33
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 25
- 230000000149 penetrating effect Effects 0.000 claims description 24
- 238000000684 flow cytometry Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 14
- 230000004069 differentiation Effects 0.000 claims description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
- 239000012192 staining solution Substances 0.000 claims description 12
- 230000035800 maturation Effects 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 210000003743 erythrocyte Anatomy 0.000 claims description 5
- 239000006166 lysate Substances 0.000 claims description 5
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000012091 fetal bovine serum Substances 0.000 claims description 3
- 230000003100 immobilizing effect Effects 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000427 antigen Substances 0.000 abstract description 7
- 102000036639 antigens Human genes 0.000 abstract description 7
- 108091007433 antigens Proteins 0.000 abstract description 7
- 230000014509 gene expression Effects 0.000 description 27
- 201000005296 lung carcinoma Diseases 0.000 description 22
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 230000028993 immune response Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 5
- 102100022338 Integrin alpha-M Human genes 0.000 description 5
- 102100022297 Integrin alpha-X Human genes 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Secondary Cells (AREA)
Abstract
Provided are an antibody combination and an analysis method for detecting a phenotype and a
function of a CD141* dendritic cell subset and a use thereof. The antibody combination for
detecting the phenotype and the function of the CD141' dendritic cell subset includes a CD141
5 antibody, a Linage antibody, an HLA-DR antibody, an IL-10 antibody, an IL-12 antibody, an
IL-23 antibody, and an IL-27 antibody. Further provided is a kit for detecting the phenotype and
the function of the CD141' dendritic cell subset. The kit can efficiently and rapidly analyze the
phenotype and the function of the CD141* dendritic cell subset in peripheral blood. The kit has
a high accuracy rate and can reduce the economic cost due to the detection of a large number of
0 surface antigen molecules. The detection and analysis method is simple and feasible and has an
important application value.
Description
METHOD FOR DETECTING A PHENOTYPE AND A FUNCTION OF A CD141* DENDRITIC CELL SUBSET AND KIT FOR USE
The present application belongs to the field of biotechnology and, in particular, related to an antibody combination and an analysis method for detecting a phenotype and a function of a CD141 dendritic cell subset and a use thereof.
CD141 dendritic cells are distributed in human peripheral blood and a dendritic cell subset that has been discovered in recent years. Clinical and basic studies have shown that the CD141 dendritic cell subset plays an important role in the development of multiple diseases, for example, malignant tumor (e.g., lung cancer, melanoma, prostate cancer, and kidney cancer), dermatitis, viral infection (e.g., HIV-1 infection), infectious diseases (e.g., malaria), and some autoimmune diseases (e.g., rheumatoid arthritis). Clinical data has shown that the CD141 dendritic cells exhibit phenotypic and functional abnormalities in all these diseases. Therefore, the clinical data of the determined phenotype and function of the CD141 dendritic cells may become an auxiliary index for clinicians to determine the development conditions and clinical treatment effects of the above diseases and is of great significance in clinical diagnosis.
Flow cytometry analysis technology has been widely used in clinical and scientific researches as the main technology of immunology. Having a primary regulatory effect in the immune system of a human body, dendritic cells are one of the hot spots in immunology research. At present, the dendritic cells are mainly detected depending on the flow cytometry analysis technology, but there are various analysis schemes for a flow cytometer for detecting the dendritic cells, without a unified and standardized mode. With the rapid changes in the studies !5 of dendritic cells, multiple different dendritic cell subtypes have been reported. However, the relatively extensive analysis schemes for the flow cytometer for detecting the dendritic cells cannot meet the clinical requirement for accurate analyses of dendritic cells of different subtypes.
CN105911292A discloses a kit for a combined analysis of CD11c and CD11b dendritic cell subsets and degrees of differentiation and functions thereof. The kit includes the following eight antibodies: a CD11c antibody, a CD80 antibody, a CD86 antibody, a CD11b antibody, an HLA-DR antibody, an IL-12 antibody, an IL-23 antibody, and an IL-27 antibody. The kit can detect the CD11c' and CD11b* dendritic cell subsets and their degrees of differentiation and functions once for a complete set of data. However, the dendritic cells have different morphologies and immune functions, there are a large number of surface antigen molecules of the dendritic cells, and different specific molecules need to be selected for detecting different dendritic cell subsets.
Studies have shown that the CD11c' and CD11b* dendritic cell subsets and the CD141' dendritic cell subset have completely different functions and play roles in different diseases. Therefore, the kit for analyzing the CD11c' and CD11b* dendritic cell subsets and their degrees of differentiation and functions cannot meet the requirement for studying the CD141' dendritic cell subset. Therefore, it is important to develop an immunoassay kit for detecting the phenotype and the function of the CD141' dendritic cell subset.
The present application provides an antibody combination and an analysis method for detecting a phenotype and a function of a CD141* dendritic cell subset and a use thereof. The antibody combination for detecting the phenotype and the function of the CD141' dendritic cell subset detects antigens including CD141, Linage, HLA-DR, IL-10, IL-12, IL-23, and IL-27. The !0 present application further provides a kit for detecting the phenotype and the function of the CD141' dendritic cell subset. The kit can efficiently and rapidly analyze the phenotype and the function of the CD141* dendritic cell subset in peripheral blood. The kit has a high accuracy rate and reduces the economic cost due to the detection of a large number of surface antigen molecules. In addition, the detection and analysis method is simple and feasible and has an !5 important application value.
In a first aspect, the present application provides an antibody combination for detecting a phenotype and a function of a CD141' dendritic cell subset. The antibody combination for detecting the phenotype and the function of the CD141' dendritic cell subset includes a CD141 antibody, a Linage antibody, an HLA-DR antibody, an IL-10 antibody, an IL-12 antibody, an IL-23 antibody, and an IL-27 antibody.
In the prior art, to identify a dendritic cell subset through flow cytometry, peripheral blood mononuclear cells generally need to be isolated and extracted. This process is complex and tedious and requires a long time period. If the cell subset is analyzed by detecting surface antigens of cell molecules, a large number of surface antigen molecules of dendritic cells generally need to be selected for detection, and only then detection accuracy and specificity can be improved. However, the detection and analysis of a large number of surface antigens takes a long time and the detection has a relatively high economic cost, which is not conducive to the rapid and efficient analysis and study of the dendritic cell subset. In the present application, the phenotype and the function of the dendritic cell subset are detected by a combination of seven antibody molecules specifically selected, which includes the CD141 antibody, the Linage antibody, the HLA-DR antibody, the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody. The formulation design can detect the phenotype and function of the CD141' dendritic cell subset with high specificity and high sensitivity, providing the basis for relevant scientific researches.
Preferably, an antibody in the antibody combination for detecting the phenotype and the function of the CD141' dendritic cell subset is labelled with a fluorescent dye.
Preferably, the fluorescent dye includes any one of BV510, BV-786, Pacific blue, PE-Cy7, AF700, eFluor660, or PE or a combination of at least two selected therefrom.
In a second aspect, the present application provides a kit for detecting a phenotype and a function of a CD141' dendritic cell subset. The kit for detecting the phenotype and the function !0 of the CD141' dendritic cell subset includes the antibody combination for detecting the phenotype and the function of the CD141' dendritic cell subset in the first aspect.
A kit commercially available at present for testing dendritic cells can only analyze the overall data of the dendritic cells in general and cannot conduct a functional analysis. With the development of scientific researches, multiple new dendritic cell subsets in human peripheral !5 blood have been discovered, such as CD141' dendritic cells, where these new dendritic cell subsets have different phenotypes and functions. The kit provided by the present application for detecting the phenotype and the function of the CD141' dendritic cell subset can analyze a proportion of a CD141' phenotype in the dendritic cell subset, determine a differentiation and maturation situation of the CD141' dendritic cell subset, and analyze functions of the CD141' dendritic cell subset.
In a third aspect, the present application provides an analysis method for detecting a phenotype and a function of a CD141* dendritic cell subset in the second aspect. The analysis method includes the following steps:
(1) pre-treating peripheral blood to isolate CD141' dendritic cells;
(2) incubating and detecting the CD141' dendritic cells by using a CD141 antibody, a Linage antibody, an HLA-DR antibody, an IL-10 antibody, an IL-12 antibody, an IL-23 antibody, and an IL-27 antibody which are labelled with different fluorescent dyes; and
(3) detecting and analyzing the CD141* dendritic cells through flow cytometry.
In the present application, the analysis method determines the dendritic cell subset in human peripheral blood and a function thereof by a one-step whole blood method. Compared with the determination of dendritic cells by peripheral blood mononuclear cell (PBMC) isolation technology, the analysis method in the present application is simple, feasible, and cost-effective. The isolation of dendritic cells by traditional PBMC isolation technology requires a large amount (generally dozens of milliliters) of blood to be collected and consumes a long time. However, in the present application, the determination by the one-step whole blood method can obtain the required complete set of information by only one drop (10-100 L) of blood of a patient. The long time required for isolating PBMCs is saved, and the determination can be achieved simply, rapidly, and with only one step. The analysis method is suitable for testing a large batch of clinical samples.
Preferably, step (1) of pre-treating the peripheral blood to isolate the CD141' dendritic cells !0 includes:
mixing the peripheral blood with an erythrocyte lysate, placing the mixture still without light, centrifuging the mixture to isolate the CD141* dendritic cells, resuspending the CD141' dendritic cells in a cell staining solution, and adding leukocyte-stimulating factors for an incubation.
!5 In the present application, the peripheral blood has a volume of 10-100 [L, which may be, for example, 10 L, 20 L, 30 L, 40 L, 50 L, 60 L, 70 L, 80 L, 90 L, or 100 L, etc.
In the present application, the peripheral blood and the erythrocyte lysate are mixed at a volume ratio of (1-10):200, which may be, for example, 1:200, 3:200, 5:200, 7:200, 9:200, or 10:200, etc.
Preferably, the mixture is placed still without light for 10-15 min, which may be, for example, 10 min, 11 min, 12 min, 13 min, 14 min, or 15 min, etc. and the mixture is placed still without light at a temperature of 20-25 °C, which may be, for example, 20 °C, 21 °C, 22 °C, 23 °C, 24 °C, or 25 °C, etc.
In the present application, the mixture is centrifuged with a centrifugal force of 300-350 g, which may be, for example, 300 g, 310 g, 320 g, 330 g, 340 g, or 350 g, etc. and the mixture is centrifuged for 5-10 min, which may be, for example, 5 min, 6 min, 7 min, 8 min, 9 min, or 10 min, etc.
Preferably, the cell staining solution includes a PBS buffer containing fetal bovine serum.
Preferably, a final concentration of the leukocyte-stimulating factors in a resuspension of the CD141' dendritic cells is 0.08-0.1 wt%, which may be, for example, 0.08 wt%, 0.09 wt%, or 0.1 wt%, etc.
Preferably, the incubation is conducted for 4-6 h, which may be, for example, 4 h, 5 h, or 6 h, etc. and the incubation is conducted at a temperature of 35-38 °C, which may be, for example, 35 °C, 36 °C, 37 °C, or 38 °C, etc.
Preferably, step (2) of incubating and detecting the CD141' dendritic cells by using the CD141 antibody, the Linage antibody, the HLA-DR antibody, the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody which are labelled with the different fluorescent dyes includes:
!0 (a) subjecting the CD141' dendritic cells to a primary incubation by using the CD141 antibody, the Linage antibody, and the HLA-DR antibody which are labelled with different fluorescent dyes;and
(b) subjecting the CD141' dendritic cells to a secondary incubation by using the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody which are labelled with different !5 fluorescent dyes.
Preferably, step (a) of subjecting the CD141' dendritic cells to the primary incubation by using the CD141 antibody, the Linage antibody, and the HLA-DR antibody which are labelled with the different fluorescent dyes includes: resuspending the CD141' dendritic cells after the incubation in step (1), subjecting a resuspension of the CD141' dendritic cells and the CD141 antibody, the Linage antibody, and the HLA-DR antibody which are labelled with the different fluorescent dyes to the primary incubation, immobilizing the CD141' dendritic cells with a formalin solution, and subjecting the CD141' dendritic cells to an incubation with light shielded.
Preferably, the formalin solution has a mass fraction of 1.5-2.5 vol%, which may be, for example, 1.5 vol%, 1.8 vol%, 2.0 vol%, 2.2 vol%, or 2.5 vol%, etc.
Preferably, the primary incubation is conducted for 25-35 min, which may be, for example, 25 min, 28 min, 30 min, 32 min, or 35 min, etc. and the primary incubation is conducted at a temperature of 20-25 °C, which may be, for example, 20 °C, 21 °C, 22 °C, 23 °C, 24 °C, or 25 °C, etc.
Preferably, the incubation with light shielded is conducted for 15-20 min, which may be, for example, 15 min, 16 min, 17 min, 18 min, or 20 min, etc. and the incubation with light shielded is conducted at a temperature of 20-25 °C, which may be, for example, 20 °C, 21 °C, 22 °C, 23 °C, 24 °C, or 25 °C, etc.
Preferably, step (b) of subjecting the CD141' dendritic cells to the secondary incubation by using the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody which are labelled with the different fluorescent dyes includes:
resuspending the CD141' dendritic cells obtained in step (a) with a cell penetrating solution, !0 centrifuging the cell penetrating solution to remove a supernatant, resuspending a cell penetrating solution for precipitation, and subjecting a resuspension of the CD141' dendritic cells and the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody which are labelled with the different fluorescent dyes to the secondary incubation.
Preferably, the cell penetrating solution is centrifuged with a centrifugal force of 300-350 g, !5 which may be, for example, 300 g, 310 g, 320 g, 330 g, 340 g, or 350 g, etc. and the cell penetrating solution is centrifuged for 5-10 min, which may be, for example, 5 min, 6 min, 7 min, 8 min, 9 min, or 10 min, etc.
Preferably, the secondary incubation is conducted for 24-26 h, which may be, for example, 24 h, 25 h, or 26 h, etc. and the secondary incubation is conducted at a temperature of 0-4 °C, which may be, for example, 0 °C, 1 C, 2 °C, 3 °C, or 4 °C, etc.
Preferably, the secondary incubation is conducted with light shielded.
Preferably, step (3) of detecting and analyzing the CD141* dendritic cells through the flow cytometry includes:
resuspending the CD141* dendritic cells after the secondary incubation with a cell penetrating solution, centrifuging the cell penetrating solution to remove a supernatant, resuspending precipitated cells with a cell staining solution, and detecting and analyzing the CD141' dendritic cells through the flow cytometry.
Preferably, the cell penetrating solution is centrifuged with a centrifugal force of 300-350 g, which may be, for example, 300 g, 310 g, 320 g, 330 g, 340 g, or 350 g, etc. and the cell penetrating solution is centrifuged for 5-10 min, which may be, for example, 5 min, 6 min, 7 min, 8 min, 9 min, or 10 min, etc.
Preferably, a method for analyzing the CD141' dendritic cells includes:
analyzing a proportion of a CD141* phenotype in the CD141' dendritic cell subset according to binding situations of the CD141 antibody and the Linage antibody to CD141 and Linage on surfaces of the CD141' dendritic cells;
analyzing a differentiation and maturation situation of the CD141' dendritic cell subset according to a binding situation of the HLA-DR antibody to HLA-DR on the surfaces of the CD141' dendritic cells; and
!0 analyzing functions of the CD141* dendritic cell subset according to binding situations of the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody to IL-10, IL-12, IL-23, and IL-27 on the surfaces of the CD141' dendritic cells.
As a preferred technical solution of the present application, the analysis method for detecting the phenotype and the function of the CD141* dendritic cell subset includes the steps described !5 below.
(1) Peripheral blood is pre-treated to isolate CD141' dendritic cells: mixing 10-100 L of peripheral blood with an erythrocyte lysate, placing the mixture still without light for 10-15 min at 20-25 °C, centrifuging the mixture for 5-10 min with a centrifugal force of 300-350 g to isolate the CD141' dendritic cells, resuspending the CD141' dendritic cells in a cell staining solution, adding leukocyte-stimulating factors, and conducting an incubation for 4-6 h at 35-38 °C, where a final concentration of the leukocyte-stimulating factors in a resuspension of the CD141 dendritic cells is 0.08-0.1 wt%.
(2) The CD141' dendritic cells are incubated and detected by using a CD141 antibody, a Linage antibody, an HLA-DR antibody, an IL-10 antibody, an IL-12 antibody, an IL-23 antibody, and an IL-27 antibody which are labelled with different fluorescent dyes:
(a) resuspending the CD141' dendritic cells after the incubation in step (1), subjecting a resuspension of the CD141' dendritic cells and the CD141 antibody, the Linage antibody, and the HLA-DR antibody which are labelled with different fluorescent dyes to a primary incubation for 25-35 min at a temperature of 20-25 °C, immobilizing the CD141' dendritic cells with a formalin solution with a mass fraction of 1.5-2.5 vol%, and subjecting the CD141' dendritic cells to an incubation with light shielded for 15-20 min at a temperature of 20-25 °C, where a volume ratio of the resuspension of the CD141' dendritic cells to the CD141 antibody, the Linage antibody, and the HLA-DR antibody is 100:(2-2.5):(2-2.5):(2-2.5); and
(b) resuspending the CD141' dendritic cells obtained in step (a) with a cell penetrating solution, centrifuging the cell penetrating solution for 5-10 min with a centrifugal force of 300-350 g to remove a supernatant, resuspending a cell penetrating solution for precipitation, and subjecting a resuspension of the CD141' dendritic cells and the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody which are labelled with different fluorescent dyes to a secondary incubation, where a volume ratio of the resuspension of the CD141' dendritic cells to the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody is !5 100:(2-2.5):(2-2.5):(2-2.5): (2-2.5), and the secondary incubation is conducted with light shielded for 24-26 h at a temperature of 0-4 °C.
(3) The CD141' dendritic cells are detected and analyzed through flow cytometry:
resuspending the CD141' dendritic cells after the secondary incubation with a cell penetrating solution, centrifuging the cell penetrating solution for 5-10 min with a centrifugal force of 300-350 g to remove a supernatant, resuspending precipitated cells with a cell staining solution, and detecting and analyzing the CD141' dendritic cells through the flow cytometry; analyzing a proportion of a CD141* phenotype in the CD141' dendritic cell subset according to binding situations of the CD141 antibody and the Linage antibody to CD141 and Linage on surfaces of the CD141' dendritic cells; analyzing a differentiation and maturation situation of the CD141' dendritic cell subset according to a binding situation of the HLA-DR antibody to HLA-DR on the surfaces of the CD141' dendritic cells; and analyzing functions of the CD141* dendritic cell subset according to binding situations of the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody to IL-10, IL-12, IL-23, and IL-27 on the surfaces of the CD141' dendritic cells.
In a fourth aspect, the present application provides a system for detecting a phenotype and a function of a CD141' dendritic cell subset. The system for detecting the phenotype and the function of the CD141' dendritic cell subset includes:
(1) a sample treatment module configured to pre-treat peripheral blood to isolate CD141' dendritic cells;
(2) a detection module configured to incubate and detect the CD141' dendritic cells by using a CD141 antibody, a Linage antibody, an HLA-DR antibody, an IL-10 antibody, an IL-12 antibody, an IL-23 antibody, and an IL-27 antibody which are labelled with different fluorescent dyes;and
(3) an analysis module configured to detect and analyze the CD141* dendritic cells through !0 flow cytometry.
In a fifth aspect, the present application provides a use of any one of the antibody combination for detecting the phenotype and the function of the CD141* dendritic cell subset in the first aspect, the kit for detecting the phenotype and the function of the CD141' dendritic cell subset in the second aspect, or the system for detecting the phenotype and the function of the CD141' !5 dendritic cell subset in the fourth aspect or a combination of at least two selected therefrom for identifying the phenotype and the function of the CD141' dendritic cell subset and/or preparing a product for identifying the phenotype and the function of the CD141' dendritic cell subset.
Preferably, the product includes a kit and/or a detection reagent for detecting malignant tumor.
Preferably, the malignant tumor includes any one of lung cancer, melanoma, prostate cancer, or kidney cancer or a combination of at least two selected therefrom.
Any numerical range described in the present application includes not only the above-listed point values but also any point values within the numerical range which are not listed. Due to the limitation of space and the consideration of simplicity, specific point values included in the range are not exhaustively listed in the present application.
Compared with the prior art, the present application has the beneficial effects described below.
(1) The analysis method for detecting the phenotype and the function of the CD141' dendritic cell subset in the present application is simple, rapid, and feasible. The dendritic cell subset in the human peripheral blood and the function thereof are determined by the one-step whole blood method. Compared with the determination of dendritic cells by peripheral blood mononuclear cell (PBMC) isolation technology, the analysis method in the present application is simple, feasible, and cost-effective. The isolation of dendritic cells by traditional PBMC isolation technology requires a large amount (generally dozens of milliliters) of blood to be collected and consumes a long time. However, in the present application, the determination by the one-step whole blood method can obtain the required complete set of information by only one drop (10-100 L) of blood of a patient. The long time required for isolating PBMCs is saved, and the determination can be achieved simply, rapidly, and with only one step. The analysis method is suitable for testing a large batch of clinical samples.
!0 (2) The result of the analysis method for detecting the phenotype and the function of the CD141' dendritic cell subset in the present application is comprehensive information. In the present application, seven antibody molecules are specifically selected as a combination which includes the CD141 antibody, the Linage antibody, the HLA-DR antibody, the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody. The formulation design can !5 analyze the proportion of the CD141' phenotype in the CD141' dendritic cell subset with high specificity and high sensitivity, determine the differentiation and maturation situation of the CD141' dendritic cell subset, and analyze the functions of the CD141' dendritic cell subset.
(3) The result of the analysis method for detecting the phenotype and the function of the CD141' dendritic cell subset in the present application has high accuracy. Compared with other techniques, the analysis scheme for detecting the phenotype and the function of the CD141' dendritic cell subset in the present application has the advantages of high sensitivity and good specificity and can obtain a more accurate and reliable detection result.
(4) An analysis scheme of the kit commercially available at present for analyzing dendritic cells can only test the overall data of the dendritic cells and cannot conduct a functional analysis. The kit for detecting the phenotype and the function of the CD141* dendritic cell subset in the present application can finely provide a complete set of data for the phenotype and the function of the latest CD141* dendritic cell subset in the human peripheral blood. Compared with the previously developed schemes, the present application tests the phenotype of the CD141' dendritic cell subset in combination with the function thereof for the first time.
FIG. 1 is an FSC-SSC scatter plot of peripheral blood cells of a healthy person in Example 3.
FIG. 2 is flow cytometry analysis plots of peripheral blood of a healthy person in Example 3.
FIG. 3 is a plot showing flow cytometry analysis results of CD141' dendritic cell subsets in peripheral blood of a healthy person/non-small-cell lung carcinoma patient in Example 3.
FIG. 4 is a statistical plot of the expression of HLA-DR in CD141' dendritic cell subsets in peripheral blood of a healthy person/non-small-cell lung carcinoma patient in Example 3.
FIG. 5 is a plot showing the expression proportions of IL-10 on CD141' dendritic cells in peripheral blood of an isotype control/healthy person/lung carcinoma patient in Example 3.
FIG. 6 is a statistical plot of the expression of IL-10 on CD141* dendritic cells in peripheral blood of a healthy person/lung carcinoma patient in Example 3.
!0 FIG. 7 is a plot showing the expression proportions of IL-12 on CD141' dendritic cells in peripheral blood of an isotype control/healthy person/lung carcinoma patient in Example 3.
FIG. 8 is a statistical plot of the expression of IL-12 on CD141* dendritic cells in peripheral blood of a healthy person/lung carcinoma patient in Example 3.
FIG. 9 is a plot showing the expression proportions of IL-23 on CD141' dendritic cells in !5 peripheral blood of an isotype control/healthy person/lung carcinoma patient in Example 3.
FIG. 10 is a statistical plot of the expression of IL-23 on CD141* dendritic cells in peripheral blood of a healthy person/lung carcinoma patient in Example 3.
FIG. 11 is a plot showing the expression proportions of IL-27 on CD141' dendritic cells in peripheral blood of an isotype control/healthy person/lung carcinoma patient in Example 3.
FIG. 12 is a statistical plot of the expression of IL-27 on CD141* dendritic cells in peripheral blood of a healthy person/lung carcinoma patient in Example 3.
Technical solutions of the present application are further described below through specific examples. Those skilled in the art are to understand that the examples described herein are used for a better understanding of the present application and are not to be construed as specific limitations to the present application.
Experiments without specific techniques or conditions specified in the examples are conducted according to techniques or conditions described in the literature in the art or product specifications. The reagents or instruments used herein without manufacturers specified are conventional products commercially available from proper channels.
Experimental materials used in the following specific examples:
flow cytometer (Cytek); Linage antibody (BioLegend); CD141 antibody (BioLegend); HLA-DR antibody (eBioscience); IL-10 antibody (BD); IL-12 antibody (BioLegend); IL-23 antibody (eBioscience); and IL-27 antibody (BioLegend).
Example 1
!0 This example provides an antibody combination for detecting a phenotype and a function of a CD141' dendritic cell subset. The antibody combination for detecting the phenotype and the function of the CD141' dendritic cell subset includes a CD141 antibody (BioLegend), a Linage antibody (BioLegend), an HLA-DR antibody (eBioscience), an IL-10 antibody (BD), an IL-12 antibody (BioLegend), an IL-23 antibody (eBioscience), and an IL-27 antibody (BioLegend).
!5 An antibody in the antibody combination for detecting the phenotype and the function of the CD141* dendritic cell subset is labelled with a fluorescent dye. The fluorescent dye for the CD141 antibody is BV510; the fluorescent dye for the Linage antibody is BV786; the fluorescent dye for the HLA-DR antibody is Pacific blue; the fluorescent dye for the IL-10 antibody is PE-Cy7; the fluorescent dye for the IL-12 antibody is AF700; the fluorescent dye for the IL-23 antibody is eFluor660; and the fluorescent dye for the IL-27 antibody is PE.
Example 2
This example provides a kit for detecting a phenotype and a function of a CD141' dendritic cell subset. The kit for detecting the phenotype and the function of the CD141' dendritic cell subset includes the antibody combination for detecting the phenotype and the function of the CD141' dendritic cell subset in Example 1.
Example 3
In this example, the kit for detecting the phenotype and the function of the CD141' dendritic cell subset in Example 2 was used for analyzing the differentiation and functions of the CD141' dendritic cell subset in the peripheral blood of a non-small-cell lung carcinoma patient (experimental group) and a healthy person (control group) and analyzing an isotype control.
(1) The peripheral blood was pre-treated to isolate CD141' dendritic cells.
100 L of vein peripheral blood of the non-small-cell lung carcinoma patient and 100 L of vein peripheral blood of the healthy adult were taken separately and anticoagulated. The whole blood of the peripheral blood was mixed with 2 mL of1x erythrocyte lysate (BioLegend), rotated and shaken for 10s, placed still without light for 15 min at 25 °C, and centrifuged in a centrifuge (for 5 min with 350 g). The supernatant was poured out. The precipitated cells were suspended in 2 !0 mL of cell staining solution (PBS solution containing 2.5% fetal bovine serum), leukocyte-stimulating factors (BD) were added, and the cells were incubated for 6 h at a constant temperature of 37 °C for later use. The final concentration of the leukocyte-stimulating factors in the resuspension of the CD141' dendritic cells was 0.1 %.
(2) The CD141' dendritic cells were incubated and detected by using a CD141 antibody, a !5 Linage antibody, an HLA-DR antibody, an IL-10 antibody, an IL-12 antibody, an IL-23 antibody, and an IL-27 antibody which were labelled with different fluorescent dyes:
(a) the CD141' dendritic cells obtained in step (1) were resuspended in 100 L of cell staining solution, the resuspension of the CD141* dendritic cells and the CD141 antibody labelled with 2 L of BV510, the Linage antibody labelled with 2 L of BV786, and the HLA-DR antibody labelled with 2 L of Pacific blue were subjected to a primary incubation for 30 min at 25 °C, 2 mL of cell staining solution was added and centrifuged for 5 min with 350 g twice, and the CD141' dendritic cells were immobilized with 2 mL of formalin solution with a mass fraction of 2% and incubated with light shielded for 20 min at 25 °C; and
(b) the CD141' dendritic cells obtained in step (a) were resuspended with 2 mL of cell penetrating solution (BioLegend), centrifuged for 5 min with 350 g twice, and resuspended with 100 L of cell penetrating solution for precipitation, and the resuspension of the CD141' dendritic cells and the IL-10 antibody labelled with 2 L of PE-Cy7, the IL-12 antibody labelled with 2 L of AF700, the IL-23 antibody labelled with 2 L of eFluor660, and the IL-27 antibody labelled with 2 L of PE were subjected to a secondary incubation with light shielded for 30 min at 25 °C.
(3) The CD141* dendritic cells were detected and analyzed through flow cytometry.
The CD141* dendritic cells after the secondary incubation were resuspended with 2 mL of cell penetrating solution, centrifuged for 5 min with 350 g to remove the supernatant, and the precipitated cells were resuspended with 0.5 mL of cell staining solution and detected and analyzed through the flow cytometry.
All information about the dendritic cell subset (characterized by the expression of CD141 and Linage), a differentiation degree (characterized by the expression of HLA-DR) and a cell function (characterized by the expression of IL-10, IL-12, IL-23 and IL-27) was obtained once !0 by the above method through the flow cytometry so that the differences between the non-small-cell lung carcinoma patient and the healthy person could be studied through the comparison of these information, thereby providing a basis for studying the immunomodulatory mechanism of the non-small-cell lung carcinoma patient.
Analysis results
!5 (1) The proportion of the CD141* phenotype of the dendritic cells was analyzed according to the binding situations of the CD141 antibody and the Linage (Lin) antibody to CD141 and Linage on the surfaces of the CD141' dendritic cells. The detection results are shown in FIG. 1. FIG. 1 is an FSC-SSC scatter plot of peripheral blood cells of the healthy person, where FSC denotes the size of the cells and SSC denotes the granularity of the cells. FIG. 2 is flow cytometry analysis plots of the peripheral blood of the healthy person, where the left plot shows the expression proportion of Linage on the dendritic cells in the peripheral blood of the healthy person, Linage-(Lin-) accounts for 12.9% of the total number of cells, the right plot shows the expression proportion of CD141 on the dendritic cells in the peripheral blood of the healthy person, and CD141 accounts for 41.9% of the total number of cells.
(2) The expression of a co-stimulatory molecule HLA-DR on the CD141 dendritic cell subset in human peripheral blood was detected by flow cytometer, and the data was used for assessing the differentiation and maturation situation of the CD141* dendritic cell subset in the human peripheral blood. FIG. 3 is a plot showing flow cytometry analysis results of the CD141 dendritic cell subsets in the peripheral blood of the healthy person/non-small-cell lung carcinoma patient. FIG. 4 is a statistical plot of the expression of HLA-DR in the CD141 dendritic cell subsets in the peripheral blood of the healthy person/non-small-cell lung carcinoma patient. In FIG. 3, a thick line represents the healthy person and a dashed line represents the non-small-cell lung carcinoma patient. The results show that the higher the HLA-DR co-expression on the surfaces of the CD141m dendritic cells, the higher the immune maturity of the CD141 dendritic cells. It can also be seen from the results in FIGS. 3 and 4 that the HLA-DR co-expression on the surfaces of the CD141* dendritic cells of the healthy person is significantly higher than that of the lung carcinoma patient, indicating that the immune maturity of the CD141 m dendritic cells in the lung carcinoma patient is significantly lower than that in the healthy person.
!0 (3) The functions of the CD141m dendritic cell subset were analyzed by determining the secretory expression of IL-10, IL-12, IL-23, and IL-27 on the surfaces of the CD141 dendritic cells through the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody.
FIG. 5 is a plot showing the expression proportions of IL-10 on the CD141m dendritic cells in the peripheral blood of the isotype control/healthy person/lung carcinoma patient. FIG. 6 is a !5 statistical plot of the expression of IL-10 on the CD141 m dendritic cells in the peripheral blood of the healthy person/lung carcinoma patient. IL-10 has the effect of inhibiting an in vivo immune function. It can be seen from the results in FIGS. 5 and 6 that the CD141 dendritic cells of the non-small-cell lung carcinoma patient secrete more IL-10 than the CD141' dendritic cells of the healthy person. The results indicate that the in vivo CD141m dendritic cells of the non-small-cell lung carcinoma patient inhibit an in vivo anti-tumor immune response by secreting more IL-10.
FIG. 7 is a plot showing the expression proportions of IL-12 on the CD141 dendritic cells in the peripheral blood of the isotype control/healthy person/lung carcinoma patient. FIG. 8 is a statistical plot of the expression of IL-12 on the CD141 dendritic cells in the peripheral blood of the healthy person/lung carcinoma patient. IL-12 is a cytokine that promotes an immune response. It can be seen from the results in FIGS. 7 and 8 that the in vivo CD141 dendritic cells of the non-small-cell lung carcinoma patient secrete less amount of IL-12 than the CD141 dendritic cells of the healthy person. The results indicate that the in vivo CD141' dendritic cells of the non-small-cell lung carcinoma patient secrete insufficient IL-12, which is very likely to affect an IL-12-mediated anti-tumor immune response.
FIG. 9 is a plot showing the expression proportions of IL-23 on the CD141 dendritic cells in the peripheral blood of the isotype control/healthy person/lung carcinoma patient. FIG. 10 is a statistical plot of the expression of IL-23 on the CD141 dendritic cells in the peripheral blood of the healthy person/lung carcinoma patient. FIG. 11 is a plot showing the expression proportions of IL-27 on the CD141 m dendritic cells in the peripheral blood of the isotype control/healthy person/lung carcinoma patient. FIG. 12 is a statistical plot of the expression of IL-27 on the CD141 m dendritic cells in the peripheral blood of the healthy person/lung carcinoma patient. It can be seen from the figures that the expression proportions of IL-23 and IL-27 on the CD141m dendritic cells of the healthy person are 17.7% and 36.6%, respectively; and the expression proportions of IL-23 and IL-27 on the CD141 m dendritic cells of the non-small-cell lung carcinoma patient are 22.2% and 38.8%, respectively.
!0 IL-23 is a cytokine that promotes an immune response. If the dendritic cells can secrete more IL-23, it indicates that the dendritic cells can promote the immune response by secreting more amount of IL-23. The results in FIGS. 9 and 10 show that IL-23 secreted by the CD141 dendritic cells of the normal healthy person is similar to IL-23 secreted by the CD141' dendritic cells of the lung carcinoma patient, indicating that the in vivo CD141m dendritic cells of the lung !5 carcinoma patient do not affect a CD141m DC-mediated immune response by regulating IL-23.
IL-27 is a cytokine that can inhibit an immune function. If the dendritic cells secrete more IL-27, it indicates that the dendritic cells have an immunosuppression effect and can inhibit an immune response by secreting more amount of IL-27. The detection results in FIGS. 11 and 12 show that the amount of IL-27 secreted by the in vivo CD141 dendritic cells of the lung carcinoma patient is not significantly different from the amount of IL-27 secreted by the CD141' dendritic cells of the normal healthy person, indicating that the in vivo CD141' dendritic cells of the lung carcinoma patient do not inhibit the immune function by secreting more amount of IL-27. The in vivo CD141 m dendritic cells of the lung carcinoma patient have an immunosuppression function compared with the in vivo CD141' dendritic cells of the healthy person.
The above results indicate that the combination of antibody molecules and the analysis method of the present application can effectively identify the CD141' dendritic cell subset in the peripheral blood and analyze the differentiation and maturation situation and functions thereof.
To conclude, in the present application, seven antibody molecules are specifically selected as a combination which includes the CD141 antibody, the Linage antibody, the HLA-DR antibody, the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody. The formulation design can analyze the proportion of the CD141' phenotype in the CD141' dendritic cell subset with high specificity and high sensitivity, determine the differentiation and maturation situation of the CD141' dendritic cell subset, and analyze the functions of the CD141' dendritic cell subset.
The applicant states that the above are the specific examples of the present application and not intended to limit the protection scope of the present application. Those skilled in the art should understand that any changes or substitutions easily conceivable by those skilled in the art within the technical scope disclosed in the present application fall within the protection scope and the disclosed scope of the present application.
Claims (11)
1. An antibody combination for detecting a phenotype and a function of a CD141' dendritic cell subset, comprising a CD141 antibody, a Linage antibody, an HLA-DR antibody, an IL-10 antibody, an IL-12 antibody, an IL-23 antibody, and an IL-27 antibody.
2. The antibody combination for detecting the phenotype and the function of the CD141' dendritic cell subset according to claim 1, wherein an antibody in the antibody combination for detecting the phenotype and the function of the CD141* dendritic cell subset is labelled with a fluorescent dye.
3. The antibody combination for detecting the phenotype and the function of the CD141' dendritic cell subset according to claim 2, wherein the fluorescent dye comprises any one of BV510, BV-786, Pacific blue, PE-Cy7, AF700, eFluor660, or PE or a combination of at least two selected therefrom.
4. A kit for detecting a phenotype and a function of a CD141 dendritic cell subset, comprising the antibody combination for detecting the phenotype and the function of the CD141' dendritic cell subset according to any one of claims 1 to 3.
5. An analysis method for detecting a phenotype and a function of a CD141' dendritic cell subset, comprising the following steps:
(1) pre-treating peripheral blood to isolate CD141' dendritic cells;
(2) incubating and detecting the CD141' dendritic cells by using a CD141 antibody, a Linage !0 antibody, an HLA-DR antibody, an IL-10 antibody, an IL-12 antibody, an IL-23 antibody, and an IL-27 antibody which are labelled with different fluorescent dyes; and
(3) detecting and analyzing the CD141* dendritic cells through flow cytometry.
6. The analysis method for detecting the phenotype and the function of the CD141' dendritic cell subset according to claim 5, wherein step (1) of pre-treating the peripheral blood to isolate !5 the CD141' dendritic cells comprises:
mixing the peripheral blood with an erythrocyte lysate, placing the mixture still without light, centrifuging the mixture to isolate the CD141* dendritic cells, resuspending the CD141' dendritic cells in a cell staining solution, and adding leukocyte-stimulating factors for an incubation;
preferably, the mixture is placed still without light for 10-15 min at a temperature of 20-25 °C; preferably, the cell staining solution comprises a PBS buffer containing fetal bovine serum; preferably, a final concentration of the leukocyte-stimulating factors in a resuspension of the CD141' dendritic cells is 0.08-0.1 wt%; preferably, the incubation is conducted for 4-6 h at a temperature of 35-38 °C.
7. The analysis method for detecting the phenotype and the function of the CD141' dendritic cell subset according to claim 5 or 6, wherein step (2) of incubating and detecting the CD141' dendritic cells by using the CD141 antibody, the Linage antibody, the HLA-DR antibody, the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody which are labelled with the different fluorescent dyes comprises:
(a) subjecting the CD141' dendritic cells to a primary incubation by using the CD141 antibody, the Linage antibody, and the HLA-DR antibody which are labelled with different fluorescent dyes;and
(b) subjecting the CD141' dendritic cells to a secondary incubation by using the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody which are labelled with different fluorescent dyes.
8. The analysis method for detecting the phenotype and the function of the CD141' dendritic cell subset according to claim 7, wherein step (a) of subjecting the CD141' dendritic cells to the primary incubation by using the CD141 antibody, the Linage antibody, and the HLA-DR antibody which are labelled with the different fluorescent dyes comprises:
!0 resuspending the CD141' dendritic cells after the incubation in step (1), subjecting a resuspension of the CD141' dendritic cells and the CD141 antibody, the Linage antibody, and the HLA-DR antibody which are labelled with the different fluorescent dyes to the primary incubation, immobilizing the CD141' dendritic cells with a formalin solution, and subjecting the CD141' dendritic cells to an incubation with light shielded;
!5 preferably, the formalin solution has a mass fraction of 1.5-2.5 vol%;
preferably, the primary incubation is conducted for 25-35 min at a temperature of 20-25 °C;
preferably, the incubation with light shielded is conducted for 15-20 min at a temperature of 20-25 °C;
preferably, step (b) of subjecting the CD141' dendritic cells to the secondary incubation by using the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody which are labelled with the different fluorescent dyes comprises: resuspending the CD141' dendritic cells obtained in step (a) with a cell penetrating solution, centrifuging the cell penetrating solution to remove a supernatant, resuspending a cell penetrating solution for precipitation, and subjecting a resuspension of the CD141' dendritic cells and the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody which are labelled with the different fluorescent dyes to the secondary incubation; preferably, the cell penetrating solution is centrifuged for 5-10 min with a centrifugal force of 300-350 g; preferably, the secondary incubation is conducted for 24-26 h at a temperature of 0-4 °C; preferably, the secondary incubation is conducted with light shielded.
9. The analysis method for detecting the phenotype and the function of the CD141' dendritic cell subset according to any one of claims 5 to 8, wherein step (3) of detecting and analyzing the CD141* dendritic cells through the flow cytometry comprises:
resuspending the CD141* dendritic cells after the secondary incubation with a cell penetrating solution, centrifuging the cell penetrating solution to remove a supernatant, resuspending precipitated cells with a cell staining solution, and detecting and analyzing the CD141' dendritic cells through the flow cytometry;
preferably, the cell penetrating solution is centrifuged for 5-10 min with a centrifugal force of 300-350 g;
!0 preferably, a method for analyzing the CD141' dendritic cells comprises:
analyzing a proportion of a CD141* phenotype in the CD141' dendritic cell subset according to binding situations of the CD141 antibody and the Linage antibody to CD141 and Linage on surfaces of the CD141' dendritic cells;
analyzing a differentiation and maturation situation of the CD141' dendritic cell subset !5 according to a binding situation of the HLA-DR antibody to HLA-DR on the surfaces of the CD141' dendritic cells; and
analyzing functions of the CD141* dendritic cell subset according to binding situations of the IL-10 antibody, the IL-12 antibody, the IL-23 antibody, and the IL-27 antibody to IL-10, IL-12, IL-23, and IL-27 on the surfaces of the CD141' dendritic cells.
10. A system for detecting a phenotype and a function of a CD141' dendritic cell subset, comprising:
(1) a sample treatment module configured to pre-treat peripheral blood to isolate CD141' dendritic cells;
(2) a detection module configured to incubate and detect the CD141' dendritic cells by using a CD141 antibody, a Linage antibody, an HLA-DR antibody, an IL-10 antibody, an IL-12 antibody, an IL-23 antibody, and an IL-27 antibody which are labelled with different fluorescent dyes;and
(3) an analysis module configured to detect and analyze the CD141* dendritic cells through flow cytometry.
11. A use of any one of the antibody combination for detecting the phenotype and the function of the CD141' dendritic cell subset according to any one of claims 1 to 3, the kit for detecting the phenotype and the function of the CD141' dendritic cell subset according to claim 4, or the system for detecting the phenotype and the function of the CD141' dendritic cell subset according to claim 10 or a combination of at least two selected therefrom for identifying the phenotype and the function of the CD141' dendritic cell subset and/or preparing a product for identifying the phenotype and the function of the CD141' dendritic cell subset;
preferably, the product comprises a kit and/or a detection reagent for detecting malignant tumor;
preferably, the malignant tumor comprises any one of lung cancer, melanoma, prostate cancer, or kidney cancer or a combination of at least two selected therefrom.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2022/077229 WO2023159343A1 (en) | 2022-02-22 | 2022-02-22 | Method for detecting phenotype and function of cd141+ dendritic cell subsets, and use kit thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022436042A1 true AU2022436042A1 (en) | 2023-09-07 |
Family
ID=83022832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022436042A Pending AU2022436042A1 (en) | 2022-02-22 | 2022-02-22 | Method for detecting a phenotype and a function of a cd141+ dendritic cell subset and kit for use |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN115004032A (en) |
| AU (1) | AU2022436042A1 (en) |
| WO (1) | WO2023159343A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987086A (en) * | 1987-11-30 | 1991-01-22 | Becton, Dickinson And Company | Method for analysis of subpopulations of cells |
| US20040219612A1 (en) * | 2003-05-02 | 2004-11-04 | Beckman Coulter, Inc. | Methods for detecting intracellular defensins in various leukocyte subpopulations |
| CN104360053B (en) * | 2014-09-22 | 2016-08-17 | 重庆医科大学附属儿童医院 | A kind of method of bone-marrow-derived lymphocyte immunophenotyping and test kit |
| CN110389221B (en) * | 2019-08-30 | 2021-03-16 | 广州中科蓝华生物科技有限公司 | Combined formula kit for analyzing phenotype and function of CD1c + dendritic cell subset and application thereof |
| CN112147326B (en) * | 2020-09-04 | 2022-04-08 | 北京大学 | Accurate detection kit for tumor immune cell subset typing |
-
2022
- 2022-02-22 WO PCT/CN2022/077229 patent/WO2023159343A1/en active Application Filing
- 2022-02-22 CN CN202280000607.2A patent/CN115004032A/en active Pending
- 2022-02-22 AU AU2022436042A patent/AU2022436042A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115004032A (en) | 2022-09-02 |
| WO2023159343A1 (en) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bianchi et al. | Erythroid‐specific antibodies enhance detection of fetal nucleated erythrocytes in maternal blood | |
| Iverson et al. | Detection and isolation of fetal cells from maternal blood using the flourescence‐activated cell sorter (FACS) | |
| AU667031B2 (en) | Methods for detection and quantitation of cell subsets within subpopulations of a mixed cell population | |
| Zhu et al. | CyTOF mass cytometry reveals phenotypically distinct human blood neutrophil populations differentially correlated with melanoma stage | |
| CN109187941B (en) | Application of CD4+ CD70+ T cell subset in preparation of kit for auxiliary diagnosis of very severe aplastic anemia | |
| US20220214347A1 (en) | Combined formulation kit for analyzing phenotype and function of cd1c+denrtic cell subset and use thereof | |
| CN111527395A (en) | Flow cytometry detection method for lymphocytes in immune cells | |
| CN116699131B (en) | HLA-DR+CD14+CD56+Use of monocytes for diagnosis in HLH | |
| Gane et al. | Flow cytometric monitoring of allergen induced basophil activation | |
| CN105223361A (en) | A kind of detect Pancytopenia Naive T cells kit, application and method | |
| CN115166252A (en) | Lymphocyte subset grouping and quantitative detection kit, detection method and application thereof | |
| CN109991417B (en) | Immune marker for tuberculosis and application | |
| CN112098646B (en) | Kit for quantitatively detecting lymphocyte subpopulation and detection method thereof | |
| EP2453243A1 (en) | Method for the diagnosis and/or follow up of the evolution of a tumor | |
| Houyhongthong et al. | Automated nucleated red blood cell count using the Mindray BC‐6800 hematology analyzer | |
| Chen et al. | Immunophenotyping by multiparameter flow cytometry | |
| AU2022436042A1 (en) | Method for detecting a phenotype and a function of a cd141+ dendritic cell subset and kit for use | |
| CN112662781A (en) | PCR-SSP method and primer for detecting red blood cell Rh blood group system RHD1227A allele | |
| Guz et al. | Molecular biology methods for blood cell antigen genotyping in reference laboratories | |
| Ruiz‐Argüelles et al. | Immunophenotypic analysis of peripheral blood lymphocytes | |
| CN117647653B (en) | Biomarker related to preeclampsia and application thereof | |
| RU2815709C1 (en) | Method of detection of cell-free dna in whole peripheral blood using flow cytometry | |
| AU2021447099A1 (en) | Method and kit for analyzing phenotype and function of CD303 | |
| Madyastha et al. | Neutrophil antigens and antibodies in the diagnosis of immune neutropenias | |
| Akanni et al. | Immunophenotyping of peripheral blood and bone marrow cells by flow cytometry |